Brief: Lantern Pharma And Ttc Oncology Establish Ai Collaboration To Expand The Clinical Development Of Drug Candidate Ttc-352
27/02/2023 13:57
Feb 27 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA AND TTC ONCOLOGY ESTABLISH AI COLLABORATION
TO
EXPAND THE CLINICAL DEVELOPMENT OF DRUG CANDIDATE TTC-352
* LANTERN PHARMA IS RECEIVING EXCLUSIVE RIGHT TO LICENSE
TTC-352,
INCLUDING ANY COLLABORATION IP DURING AN EXCLUSIVE OPTION PERIOD
Source text for Eikon: ID:nBw9G63VKa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments